QUEBEC CITY, June 29, 2011 /PRNewswire/ - Aeterna Zentaris
Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a
late-stage drug development company specialized in oncology and
endocrine therapy, announced today that it has entered into an
"At-the-Market" ("ATM") Sales Agreement, dated June 29, 2011, with McNicoll, Lewis &
Vlak LLC ("MLV"), under which the Company may, at its
discretion, from time to time during the 24-month term of the
agreement, sell up to a maximum of 9,500,000 of its common shares
through ATM issuances on the NASDAQ Stock Market. MLV will act as
sales agent for any sales made under the ATM. The common shares
will be sold at market prices prevailing at the time of the sale of
common shares, and, as a result, prices may vary.
In connection with the signature of the ATM Sales Agreement with
MLV, the Company has filed a prospectus supplement dated
June 29, 2011 to its U.S. shelf
prospectus, dated July 15, 2010,
forming part of its U.S. registration statement on Form F-10 with
the United States Securities and
Exchange Commission ("SEC") as well as a prospectus supplement to
its Canadian final base shelf prospectus dated July 15, 2010.
The U.S. shelf prospectus and the supplement thereto have been
filed with the SEC on the SEC's website (www.sec.gov) and the
Canadian final base shelf prospectus and the supplement thereto
have been filed on the SEDAR website maintained by the Canadian
Securities Administrators at www.sedar.com. Alternatively,
MLV will provide copies of the U.S. documents upon request by
contacting McNicoll, Lewis & Vlak LLC, Attention: Randy Billhardt, 1251 Avenue of the Americas,
41st Floor, New York,
NY 10020, or by calling 212-580-5881, while copies of the
Canadian documents may be obtained by contacting the Company's
Investor Relations department directly by calling (418) 652-8525,
ext. 265.
This press release does not and shall not constitute an offer to
sell or the solicitation of an offer to buy any of the common
shares, nor shall there be any sale of the common shares in any
state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of such state or jurisdiction.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a late-stage oncology drug development
company currently investigating potential treatments for various
cancers including colorectal, multiple myeloma, endometrial,
ovarian, prostate and bladder cancer. The Company's innovative
approach of "personalized medicine" means tailoring treatments to a
patient's specific condition and to unmet medical needs. Aeterna
Zentaris' deep pipeline is drawn from its proprietary discovery
unit providing the Company with constant and long-term access to
state-of-the-art therapeutic options. For more information please
visit www.aezsinc.com.
SOURCE AETERNA ZENTARIS INC.